Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15179MR)

This product GTTS-WQ15179MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15179MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ181MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ8208MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15518MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ7452MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ12251MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ12584MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ6873MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ10153MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW